Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...
Adjuvant pembrolizumab improved recurrence-free survival among patients with resected Merkel cell carcinoma, but not significantly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback